Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside

Company Overview - Illumina Inc. (ILMN) is recognized for its advanced genomic sequencing and multiomics solutions, which facilitate precision oncology research, biomarker discovery, and targeted therapies [4] - The company has launched Illumina Connected Multiomics, a cloud-based platform aimed at integrating and analyzing large multiomic datasets [3] Analyst Insights - TD Cowen has raised its price target for Illumina Inc. to $140 from $115 while maintaining a Hold rating, indicating a positive outlook for the company [2] - Analysts suggest that recent share price increases have set elevated expectations, but there is still potential for upside in 2026 [2] Industry Position - Illumina's AI-driven platforms are positioned to accelerate cancer diagnostics, drug development, and personalized treatment strategies, establishing the company as a leader in oncology-focused genomic innovation [4]